|
2022
|
Invention
|
Recombinant antibody having unique glycan profile produced by cho host cell with edited genome an... |
|
|
Invention
|
Liquid formulation of humanized antibody for treating il-6-mediated diseases.
The invention rela... |
|
|
Invention
|
Anti-b7-h3 antibody and application thereof.
Disclosed is an anti-B7-H3 antibody and application... |
|
|
Invention
|
Drug conjugate and use thereof.
A drug conjugate, such as an antibody drug conjugate, and the us... |
|
|
Invention
|
Anti-il-5 antibody formulation, preparation method therefor and use thereof.
Provided is an anti... |
|
2021
|
Invention
|
Anti-cldn18.2 antibody, and preparation method therefor and use thereof.
The present invention r... |
|
|
Invention
|
Stable antibody formulation, preparation method therefor, and applications thereof.
Related to t... |
|
|
Invention
|
Use of anti-ox40 antibody in treatment of tumor or cancer.
The use of an anti-OX40 antibody or a... |
|
|
Invention
|
Bispecific antibody and use thereof.
The present invention provides a bispecific antibody and us... |
|
|
Invention
|
Use of anti-pd-1 antibody in combination therapy.
Disclosed are anti-PD-1 antibodies and use of ... |
|
|
Invention
|
Anti-pd-l1 antibody and use thereof.
Disclosed are anti-PD-L1 antibodies and use of anti-PD-1 an... |
|
|
Invention
|
Anti-cd47 antibody and use thereof.
CD47 antibodies and use thereof are disclosed, particularly ... |
|
|
Invention
|
Anti-her2 antibody and use thereof.
The present invention provides an anti-HER2 antibody and use... |
|
|
Invention
|
Antibody and fusion protein for treating coronaviruses and use thereof.
The present invention pr... |
|
|
Invention
|
Development and application of immune cell activator.
The development and use of an anti-OX40 an... |
|
|
Invention
|
Anti-tnf-a antibody formulation, preparation method therefor and use thereof.
An anti-TNF-α anti... |
|
2020
|
Invention
|
Anti-ctla-4 monoclonal antibody, preparation method therefor, and application thereof.
Disclosed... |
|
|
Invention
|
Anti-tigit immunosuppressant and application thereof.
The present invention provides an anti-TIG... |
|
|
Invention
|
Antibody binding to pd-1.
Disclosed herein are antibodies that bind to PD-1, comprising one or m... |
|
2019
|
Invention
|
Long-acting and low-toxic recombinant anti-vegf humanized monoclonal antibody and production meth... |
|
2018
|
Invention
|
A liquid formulation of humanized antibody for treating il-6-mediated diseases.
The invention re... |
|
|
Invention
|
Compounds and methods for the treatment of trop2 positive diseases. The present invention general... |
|
2017
|
Invention
|
Compounds and methods for the treatment of erb b2/neu positive diseases.
Disclosed herein are an... |
|
2016
|
Invention
|
Maytansinoid derivatives.
Disclosed herein are maytansinoid drug linker derivatives which can be... |
|
2015
|
Invention
|
Compounds and methods for the treatment of erb b2/neu positive diseases. Disclosed herein are ant... |
|
2014
|
Invention
|
Bispecific antibodies which bind egfr and vegf. Provided are bispecific antibodies having a full-... |
|
2013
|
Invention
|
Compounds and methods for the treatment of cd20 positive diseases.
Disclosed herein are anti-CD2... |
|
|
Invention
|
Compounds and methods for the treatment of egfr positive diseases. Disclosed herein are anti-EGFR... |
|
|
Invention
|
Preparation of maytansinoid esters. Provided are efficient methods for direct coupling of a mayta... |
|
|
Invention
|
Maytansinoid derivatives. Disclosed herein are maytansinoid drug linker derivatives which can be ... |
